Norlyroc is mini-pill devoted to increasing the viscosity of cervical mucus. The main component is norethindrone.
Indications for use
Mechanism of action
The mechanism of progestin oral contraceptives is based, first of all, on the change in the viscosity of the cervical mucus, which becomes thicker forming an impassable barrier for spermatozoa. This significantly reduces the mobility and viability of spermatozoa preventing their penetration into the egg. As an additional effect, the egg slows down the movement through the fallopian tubes, as well as changes in the endometrium, which excludes the possibility of attachment and further development of the embryo: if the sperm passes through the cervical mucus and fertilizes the egg, then under the influence of this mini-pill, the uterine mucosa changes and cannot accept a fertilized egg, that is, the egg cannot be implanted.
Mode of application and dosage
Norlyroc should be taken on a daily basis at about the same time in the sequence indicated on the blister pack. It is necessary to take 1 pill per day for 28 consecutive days. During the latest 7 pills, the menstrual bleeding usually occurs. It usually begins 2-3 days after the last pill is taken and may not end by the time the next package begins.
- Hypersensitivity to the drug components including norethindrone;
- Vein thrombosis at present or in anamnesis;
- Thrombosis of arteries now diagnosed or prior transferred (for example, myocardial infarction);
- Hereditary or acquired predisposition to venous or arterial thrombosis;
- Predisposition to thrombosis (including transient ischemic attack, angina pectoris), incl. in the medical history;
- Heart valve disease, atrial fibrillation, uncontrolled hypertension of a complicated form;
- Serious surgical intervention with a long-lasting fixation;
- Smoking over 35 years old;
- Hepatic failure;
- Cerebrovascular: diagnosed or prior transferred;
- Severe or multiple risk factors for arterial thrombosis including diabetes mellitus complicated vascular problems, high blood pressure, severe dyslipoproteinemia;
- Pancreatitis including the prior transferred, if expressed hypertriglyceridemia was observed;
- Severe hepatic disease: presently diagnosed or prior transferred;
- Severe chronic or acute renal failure;
- Liver tumors: diagnosed or prior transferred;
- Hormone-dependent malignant diseases of the reproductive system;
- Vaginal bleeding of unknown etiology;
- Migraine with focal neurological symptoms in the medical history;
- Hereditary intolerance to galactose and lactase insufficiency.
- Nervous system: often – headache, emotional lability, depression; infrequently – decreased libido; rarely – increase in libido.
- Endocrine system: often – violations of the menstrual cycle, intermenstrual bleeding, pain in the mammary glands; rarely – secretion from the mammary glands.
- Organs of senses: rarely – hearing loss, intolerance of contact lenses.
- Digestive system: often – nausea, pain in the abdomen; infrequently – vomiting, diarrhea.
- Skin and subcutaneous tissue: infrequently – acne, eczema, skin rash, urticaria, erythema nodosum, erythema multiforme, pruritus, chloasma (especially if pregnant women have a history of chloasma).
- Vascular system: often – migraine; infrequently – increase or decrease in blood pressure; rarely – thrombosis (venous and arterial), thromboembolism.
- Immune system: rarely – bronchospasm.
- Reproductive system and mammary glands: often – acyclic vaginal bleeding (spotting bloody discharge or breakthrough uterine bleeding), tenderness, enlargement of mammary glands, candidiasis; infrequently – vaginitis; rarely – secretions from the mammary glands, increased vaginal secretion.
It is possible to reduce the effectiveness and development of breakthrough bleeding with the simultaneous administration of this drug with preparations that induce microsomal hepatic enzymes. In particular, this interaction is possible with the use of phenytoin, barbiturates, carbamazepine, rifabutin, primidone, rifampicin, oxcarbazepine, ritonavir, topiramate, griseofulvin, felbamate and St. John’s wort preparations.
If the combined use of these drugs is necessary, it is recommended to additionally use the barrier method of contraception during the administration of these drugs, and also within 28 days after the end of therapy with the above drugs.
With the simultaneous use of Norlyroc and enterosorbent means, a reduction in the contraceptive effect is possible.
It is impossible to exclude the possibility of drug influence on the metabolism of other drugs (it is recommended to study the interaction of individual drugs with progestogens to prevent possible interactions).
What if I miss a dose?
The delay is allowed in the reception of mini-pills up to 3 hours. If you are more than 3 hours late, immediately take the pill, but ALWAYS use other contraceptives for the next 48 hours. It is best to additionally use other contraceptives for 7 days.
Norlyroc and pregnancy
During pregnancy and lactation, the use of the drug is contraindicated.